Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US biopharmaceutical firm Introgen Therapeutics has made an approximate $3 million equity investment in SR Pharma, a UK-based biotech company, resulting in an 8.3% stake in SR Pharma's issued share capital.
Subscribe to our email newsletter
Introgen’s investment will be used to develop SR Pharma’s leading siRNA technology in the oncology area, including atuPLEX, its proprietary delivery system, which it has accessed through its recent acquisition of Atugen AG, as well as other products and technologies of strategic interest to both SR Pharma and Introgen.
David Nance, president and CEO of Introgen, said; “SR Pharma has gained access to an innovative technology within the field of RNAi and complementary delivery technologies through its recent acquisition of the Atugen AG in Berlin, Germany. With a combination of our respective competencies, I believe value can be added for shareholders of both companies.”
RNA-mediated interference, or RNAi, is a new approach for achieving targeted gene silencing of pathological genes using complementary double stranded RNA. It harnesses a naturally occurring cellular mechanism, in order to prevent the expression of target genes by inducing degradation of the target messenger RNA.
Iain Ross, chairman of SR Pharma said; “We have identified a number of initiatives upon which the two companies may collaborate and look forward to making further announcements about collaborative activities as events present themselves.”